As direct-to-patient deliveries of temperature-sensitive medications rise, the pharmaceutical industry is racing to protect drug integrity from factory to front door. Biologics, vaccines, and other sensitive therapies now dominate demand, and any lapse in the cold chain can compromise effectiveness and cost companies millions. The market for temperature-controlled packaging is expanding rapidly. Valued at roughly $55 billion in 2024, it is projected to exceed $200 billion by 2032, according to Stratview R ...